Alexa Moreno-Mirón
Research Subjects
Research Interests
Alexa Moreno-Mirón has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Guillermo J. Ruiz-Argüelles
Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, México
2 shared publications - José Manuel Moreno-Mirón
Departamento de Oncología y Hematología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Col. Belisario Domínguez Sección XVI, Tlalpan, 14080 Mexico City, Mexico
2 shared publications - Robert Peter Gale
Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK
2 shared publications - Ana Paola Rivera-Aguilar1 shared publication
- Moisés Manuel Gallardo-Pérez
Universidad Popular Autónoma del Estado de Puebla, Puebla, México
1 shared publication
Latest Publications
- 21 September 2026
- Published by S. Karger AG in Acta Haematologica
- p. 1
Helicobacter pylori in Haematology: Contextualising Established and Emerging Associations
- 21 September 2026
- Published by S. Karger AG in Acta Haematologica
- p. 1
Helicobacter pylori in Haematology: Contextualising Established and Emerging Associations
- Open Access
- 29 January 2026
- Published by S. Karger AG in Acta Haematologica
- p. 1-11
The Gastro-Intestinal Microbiota in Haematology
Background: The gastro-intestinal microbiota is a key regulator of systemic immunity and inflammatory tone and it contributes to normal haematopoiesis through microbial metabolites, barrier integrity, and host-microbe immune signalling. Disruption of this has been increasingly linked to the development, clinical course, and treatment-related complications of haematological disorders, including clonal haematopoiesis of indeterminate potential (CHIP), leukaemias, and plasma cell neoplasms (PCNs). Summary: This review synthesises current evidence on how gut microbiota composition and function intersect with haematopoietic regulation and haematological disease biology. We summarise proposed mechanisms – including microbe-derived metabolites (e.g., short-chain fatty acids), pattern-recognition receptor signalling, intestinal permeability, and cytokine-mediated inflammation – that may influence haematopoietic stem and progenitor cell behaviour and immune cell differentiation. We then discuss disease-specific associations of dysbiosis with CHIP, leukaemias, and PCN, as well as the impact of common haematology interventions (antibiotics, chemotherapy, immunomodulatory therapies, and transplantation) on microbial ecology and downstream clinical outcomes. Finally, we highlight methodological challenges and outline priorities for longitudinal, mechanistic, and multi-omics studies to enable microbiota-informed risk stratification and therapeutic modulation. Key Messages: (1) The gut microbiota influences haematopoiesis via immune signalling, microbial metabolites, and maintenance of mucosal barrier function. (2) Dysbiosis is associated with CHIP, leukaemias, and PCN, and may contribute through chronic inflammation and altered immune homeostasis. (3) Haematological therapies frequently reshape the microbiota; these changes may affect infection risk, treatment tolerance, and outcomes. (4) Current evidence is largely associative; rigorously designed longitudinal and interventional studies are needed to establish causality and guide clinical translation.
- 29 January 2026
- Published by S. Karger AG in Acta Haematologica
- p. 1-11
Open AccessThe Gastro-Intestinal Microbiota in Haematology
Background: The gastro-intestinal microbiota is a key regulator of systemic immunity and inflammatory tone and it contributes to normal haematopoiesis through microbial metabolites, barrier integrity, and host-microbe immune signalling. Disruption of this has been increasingly linked to the development, clinical course, and treatment-related complications of haematological disorders, including clonal haematopoiesis of indeterminate potential (CHIP), leukaemias, and plasma cell neoplasms (PCNs). Summary: This review synthesises current evidence on how gut microbiota composition and function intersect with haematopoietic regulation and haematological disease biology. We summarise proposed mechanisms – including microbe-derived metabolites (e.g., short-chain fatty acids), pattern-recognition receptor signalling, intestinal permeability, and cytokine-mediated inflammation – that may influence haematopoietic stem and progenitor cell behaviour and immune cell differentiation. We then discuss disease-specific associations of dysbiosis with CHIP, leukaemias, and PCN, as well as the impact of common haematology interventions (antibiotics, chemotherapy, immunomodulatory therapies, and transplantation) on microbial ecology and downstream clinical outcomes. Finally, we highlight methodological challenges and outline priorities for longitudinal, mechanistic, and multi-omics studies to enable microbiota-informed risk stratification and therapeutic modulation. Key Messages: (1) The gut microbiota influences haematopoiesis via immune signalling, microbial metabolites, and maintenance of mucosal barrier function. (2) Dysbiosis is associated with CHIP, leukaemias, and PCN, and may contribute through chronic inflammation and altered immune homeostasis. (3) Haematological therapies frequently reshape the microbiota; these changes may affect infection risk, treatment tolerance, and outcomes. (4) Current evidence is largely associative; rigorously designed longitudinal and interventional studies are needed to establish causality and guide clinical translation.